-
Deutsche Bank Discusses Eli Lilly Investor Meeting
Friday, July 1, 2011 - 7:51am | 104Deutsche Bank is out with a research report on Eli Lilly (NYSE: LLY) after the company held its investor meeting yesterday. It has a Hold rating and a $38.50 price target on shares. In a note to clients, Deutsche Bank writes, "LLY remains on course with its long term growth plans, and as expected...
-
Piper Jaffray Overweight On Allergan
Friday, July 1, 2011 - 7:43am | 189Piper Jaffray has an Overweight rating and a $91 price target on shares of Allergan Inc. (NYSE: AGN). In a note to clients, Piper Jaffray writes, "We believe Allergan is well-positioned for a solid 2Q, and with strength across a number of franchises, we could see meaningful upside to the Street...
-
J.P. Morgan Downgrading BioMimetic Therapeutics
Friday, July 1, 2011 - 7:33am | 148J.P. Morgan Chase & Co. is downgrading shares of BioMimetic Therapeutics (NASDAQ: BMTI) to Neutral from Overweight, and is cutting the price target to $5. In a note to clients, J.P. Morgan Chase & Co. writes, "We are lowering our rating on BMTI from Overweight to Neutral on the heels of...
-
Merck Receives Approval to Market GARDASIL, ZOLINZA and CUBICIN in Japan
Friday, July 1, 2011 - 7:01am | 43Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Japanese Ministry of Health, Labour and Welfare approved three products - GARDASIL, ZOLINZA and CUBICIN – for use in Japan.
-
JP Morgan Downgrades BioMimetic Therapeutics To Neutral, Lowers PT To $5
Friday, July 1, 2011 - 6:17am | 28JP Morgan has downgraded BioMimetic Therapeutics (NASDAQ: BMTI) from Overweight to Neutral and has lowered the price target from $10 to $5.
-
Stocks to Watch for 07/1/11: Fresh 52 Week Highs and Lows
Friday, July 1, 2011 - 4:16am | 2869Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Thursday's trading session: 1) Walter Investment Company (NYSE: WAC): Shares of Walter Investment hit a 52-week...
-
16 Stocks That Only Go Up
Thursday, June 30, 2011 - 3:13pm | 295This is by far, one of my favorite stock screens that I run. I have probably found more winning stocks (and big % ones at that) off of this screen, than any other one that I run. These stocks make it a habit to trade on their own merits and not that of the market itself. They are often overlooked,...
-
16 Stocks That Only Go Up
Thursday, June 30, 2011 - 3:13pm | 294This is by far, one of my favorite stock screens that I run. I have probably found more winning stocks (and big % ones at that) off of this screen, than any other one that I run. These stocks make it a habit to trade on their own merits and not that of the market itself. They are often overlooked,...
-
16 Stocks That Only Go Up
Thursday, June 30, 2011 - 3:13pm | 315This is by far, one of my favorite stock screens that I run. I have probably found more winning stocks (and big % ones at that) off of this screen, than any other one that I run. These stocks make it a habit to trade on their own merits and not that of the market itself. They are often overlooked,...
-
Calls Purchased on Warner Chilcott
Thursday, June 30, 2011 - 11:01am | 116Shares of Warner Chilcott plc (NASDAQ: WCRX) are higher on the session by 1.97%, currently trading at $24.34. The stock has been moving largely higher over the past five weeks and is currently trading above the 200-day moving average. Options traders are buying calls on the name today. A short...
-
Morgan Stanley Provides Color on Bristol Myers Squibb
Thursday, June 30, 2011 - 8:46am | 136Morgan Stanley Provided Color on Bristol Myers Squibb (NYSE: BMY). In a research report published today, Morgan Stanley states, “We expect 2013 EPS guidance to remain unchanged at minimum $1.95. In conjunction with long-term strategic planning in June, we expect Bristol to update its 2013...
-
Endo Announces Topline Results From Phase 2 Study
Thursday, June 30, 2011 - 8:33am | 71Endo Pharmaceuticals (NASDAQ: ENDP) announced today topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study...
-
Duncan-Williams Has Buy On Endo Pharmaceuticals Holdings
Thursday, June 30, 2011 - 8:17am | 118Duncan-Williams has a Buy rating and a $51 price target on shares of Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP). In a note to clients, Duncan-Williams writes, "We updated our model to include 3Q11 and 13 days of AMS sales in June. We also converted our therapeutic models from IMS to...
-
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
Thursday, June 30, 2011 - 8:00am | 138Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application, which was submitted on April 15, 2011, for CORLUX, a glucocorticoid receptor type II (GR-II) antagonist, for the treatment of the...
-
A Peek Into The Market Before The Trading Starts
Thursday, June 30, 2011 - 7:27am | 399Pre-open movers US stock futures are slightly higher this morning, as investors are awaiting jobless claims and Chicago PMI data. Futures on the Dow Jones Industrial Average surged 16 points to 12,234.00 and futures on the S&P 500 stock index rose 1 point to 1,305.30. Nasdaq 100 futures gained...